title: Institutional review boards must conduct safety review.
authors.affiliation: The Deem Corporation, P.O. Box 44069, Omaha, NE 68144, USA.
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Maloney
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced; D000068579:Celecoxib; D026661:Clinical Trials Data Monitoring Committees; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000331:legislation & jurisprudence; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D028744:Ethics Committees, Research; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D009316:National Institutes of Health (U.S.); D011720:Pyrazoles / Q000009:adverse effects*; D035842:Research Subjects; D012449:Safety; D013449:Sulfonamides / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib